Table 3 CMR findings (with controls)
Total MM Patients (N = 64) | CPEO/KSS (N = 33) | MELAS/-like (N = 11) | MERRF (N = 3) | Other MM (N = 17) | Controls (N = 25) | p value | |
|---|---|---|---|---|---|---|---|
LV end-diastolic volume index ml/m2 | 67 ± 18 | 61 ± 14*§ | 85 ± 24 | 73 ± 15 | 66 ± 14* | 76 ± 17 | 0.001 |
LV end-systolic volume index, ml/m2 | 25 ± 2 | 21 ± 8* | 37 ± 20 | 28 ± 10 | 24 ± 7* | 27 ± 8 | 0.002 |
LV mass index, g/m2 | 56 ± 23 | 49 ± 11* | 90 ± 35 | 58 ± 17 | 50 ± 12* | 50 ± 12* | <0.001 |
LV ejection fraction, % | 66 ± 8 | 66 ± 7 | 59 ± 12 | 62 ± 5 | 65 ± 6 | 65 ± 5 | 0.09 |
LV ejection fraction <60 %, n (%) | 18 (28) | 8 (24) | 6 (55) | 1 (33) | 3 (18) | 2 (8) | 0.07 |
LV mass/ end-diastolic volume, g/ml | 0.84 ± 0.27 | 0.84 ± 0.24*§ | 1.07 ± 0.31§ | 0.71 ± 0.06 | 0.72 ± 0.22* | 0.67 ± 0.11 | <0.001 |
Max. wall thickness, mm | 10 ± 3 | 9 ± 2* | 14 ± 3§ | 10 ± 2 | 10 ± 2* | 8 ± 2 | <0.001 |
LV hypertrophy in absence of AHT, n (%) | 14 (22) | 3 (9)* | 9 (82)§ | 1 (33) | 1 (6)* | 0 (0)* | <0.001 |
RV end-diastolic volume index ml/m2 | 66 ± 14 | 63 ± 12 | 69 ± 18 | 65 ± 9 | 72 ± 15 | 72 ± 18 | 0.21 |
RV end-systolic volume index, ml/m2 | 30 ± 9 | 29 ± 9 | 30 ± 10 | 32 ± 7 | 33 ± 10 | 31 ± 9 | 0.49 |
RV ejection fraction, % | 55 ± 10 | 55 ± 11 | 57 ± 8 | 51 ± 5 | 54 ± 10 | 57 ± 8 | 0.70 |
LGE presence, n (%) | 21 (33) | 12 (36)§ | 8 (73)§ | 0 (0) | 1 (6)* | 1 (4) | <0.001 |
Non-ischemic LGE presence, n (%) | 19 (30) | 10 (30)§* | 8 (73)§ | 0 (0) | 1 (6)* | 0 (0) | <0.001 |
Any abnormal CMR findings, n (%) | 34 (53) | 18 (55) | 10 (91) | 1 (33) | 5 (29) | 3 (12) | <0.001 |